CLINICAL_TRIALS ClinicalTrials.gov record update

Clinical Efficacy and Benefit of Reducing Metabolic Syndrome by Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics (MARTAs) Treated Schizophrenia Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04898270
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:09.847194+00:00
Published At: 2021-05-24T00:00:00+00:00
Record Updated At: 2021-05-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Schizophrenia; Psychosis", "Metabolic Syndrome", "Flupentixol", "Antipsychotic Agents", "Central Nervous System Diseases", "Clinical Therapy", "Olanzapine", "Quetiapine"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-05-24"
protocolSection.identificationModule.nctId: "NCT04898270"
protocolSection.identificationModule.officialTitle: "Clinical Efficacy and Benefit of Reducing Metabolic Syndrome by Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics (MARTAs) Treated Schizophrenia Patients"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.